Guardant Health, Inc. - Common Stock (NQ:GH)

Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions

February 02, 2026

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps...

3 Unpopular Stocks We Think Twice About

February 01, 2026

This genomics stock appears to be at an inflection point.

Should You Buy Guardant Health Before Feb. 19? ↗

January 30, 2026

Via The Motley Fool

Topics Earnings

Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026

January 29, 2026

Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer

January 22, 2026

Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform

January 19, 2026

Guardant Health (NASDAQ:GH): Strongest Q3 Results from the Testing & Diagnostics Services Group

January 14, 2026

Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Guardant Health (NASDAQ:GH) and its peers.

CS Diagnostics (OTCQB: CSDX) Advances Infection Control and Oncology Innovation Plus – IVP, SAFX, JTAI, OCG, BMXI Inside

January 14, 2026

Via AB Newswire

Topics Intellectual Property

GRAIL Surges as Canaccord Genuity Sets Ambitious $105 Price Target Following Robust 2025 Growth

January 13, 2026

In a resounding vote of confidence for the future of multi-cancer early detection (MCED), Canaccord Genuity reiterated its "Buy" rating for GRAIL (Nasdaq: GRAL) on Tuesday, January 13, 2026, setting an...

Adaptive Biotechnologies Surges as Preliminary 2025 Results Signal a Turning Point in MRD Commercialization

January 13, 2026

Shares of Adaptive Biotechnologies (NASDAQ: ADPT) soared on Tuesday, January 13, 2026, after the life sciences company announced preliminary fourth-quarter and full-year 2025 financial results that...

On January 12, 2026, the diagnostic sector witnessed a seismic shift as shares of Biodesix (Nasdaq: BDSX) surged more than 40% in early trading, following the release of preliminary full-year 2025...

Biodesix Shares Rocket 42% on Record FY2025 Results and Path to Profitability

January 12, 2026

Topics Artificial Intelligence Death

Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results

January 11, 2026

Guardant Health’s Shield Blood Test for Colorectal Cancer Screening Now Available for U.S. Military Members and Families

January 08, 2026

As the financial markets open for the 2026 calendar year, BTIG has released its highly anticipated "Top Picks" report for the first half of the year, signaling a transition from the speculative fervor...

BTIG's Top Stock Picks for H1 2026: Navigating the New 'Application' Era

January 02, 2026

Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.

Topics Artificial Intelligence Economy

1 Growth Stock Set to Flourishand 2 We Avoid

January 01, 2026

The Year-End Biotech Chill: Adaptive Biotechnologies Braces for J.P. Morgan Crucible Amid Market Sell-Off

December 30, 2025

As the final trading days of 2025 wind down, the biotechnology sector finds itself caught in a paradoxical "bifurcated" squeeze. While the broader indices have touched record highs this year, a sharp...

Topics Artificial Intelligence Economy Intellectual Property

Guardant Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference

December 29, 2025

Why a Top Biotech Holder Sold 115,000 Mirum Shares but Still Ended Up With $185 Million on the Line ↗

December 28, 2025

Selling shares usually signals doubt, but in this case the math points to something very different happening beneath the surface.

Via The Motley Fool

Topics Regulatory Compliance

Q3 Earnings Roundup: Cardinal Health (NYSE:CAH) And The Rest Of The Healthcare Providers & Services Segment

December 17, 2025

Looking back on healthcare providers & services stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Cardinal Health (NYSE:CAH) and its peers.

Q3 Rundown: The Ensign Group (NASDAQ:ENSG) Vs Other Healthcare Providers & Services Stocks

Topics Economy

December 15, 2025

Looking back on healthcare providers & services stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including The Ensign Group (NASDAQ:ENSG) and its peers.

Guardant Health Announces Collaboration with Trial Library to Increase Access to Cancer Clinical Trials Across the U.S.

December 11, 2025

Guardant Health and Policlinico Gemelli Launch In-House Liquid Biopsy Testing Service in Italy

December 09, 2025

A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south. While some investors embrace risk, mistakes can be costly for those who aren’t prepared.

3 Volatile Stocks Walking a Fine Line

December 07, 2025

Guardant Health to Present 14 Abstracts Demonstrating the Power of Multiomic Liquid Biopsy Tests in Predicting Outcomes and Tailoring Treatment for Early and Metastatic Breast Cancer at the 2025 San Antonio Breast Cancer Symposium

December 05, 2025

Shares of diagnostics company Guardant Health (NASDAQ:GH) jumped 1.8% in the afternoon session after Morgan Stanley raised its price target on the stock, reflecting heightened optimism about the...

Why Guardant Health (GH) Stock Is Up Today

December 03, 2025

Healthcare Providers & Services Stocks Q3 Recap: Benchmarking AMN Healthcare Services (NYSE:AMN)

December 01, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at AMN Healthcare Services (NYSE:AMN) and its peers.

Alignment Healthcare, Hims & Hers Health, Surgery Partners, Guardant Health, and Pediatrix Medical Group Stocks Trade Up, What You Need To Know

November 24, 2025

A number of stocks jumped in the afternoon session after a Politico report revealed that the White House plans to pitch a two-year extension of Obamacare subsidies. The proposal would extend subsidies...

What a time it’s been for Guardant Health. In the past six months alone, the company’s stock price has increased by a massive 171%, setting a new 52-week high of $106.25 per share. This was partly due...

Topics Economy

Guardant Health (GH): Buy, Sell, or Hold Post Q3 Earnings?

November 23, 2025

Healthcare Providers & Services Stocks Q3 In Review: Pediatrix Medical Group (NYSE:MD) Vs Peers

November 23, 2025

As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the healthcare providers & services industry, including Pediatrix Medical Group...